{"created":"2023-06-19T07:25:26.468423+00:00","id":13246,"links":{},"metadata":{"_buckets":{"deposit":"11b8a52e-01e7-4f17-862b-dc42621ade08"},"_deposit":{"created_by":20,"id":"13246","owners":[20],"pid":{"revision_id":0,"type":"depid","value":"13246"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00013246","sets":["212:260:312"]},"author_link":["19340","19339","19343","19342","19341"],"item_3_biblio_info_3":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-12","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"187","bibliographicPageStart":"181","bibliographicVolumeNumber":"6","bibliographic_titles":[{"bibliographic_title":"日本腎臓病薬物療法学会誌"}]}]},"item_3_text_4":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_text_value":"10.24595/jjnp.6.3_181"}]},"item_3_textarea_2":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_textarea_value":"Aluminum hydroxide and magnesium hydroxide have been reported to attenuate the action of rosuvastatin, an HMG-CoA reductase inhibitor, but the mechanism is not fully understood. Lanthanum carbonate contains the polyvalent metal lanthanum, which may interact similarly with HMG-CoA reductase inhibitors. Therefore, we surveyed 29 patients being treated chronically with rosuvastatin who began treatment with lanthanum carbonate. The study consisted of 29 patients, further investigated six patients in the rosuvastatin group and 23 patients in the non-rosuvastatin group. Low-density lipoprotein (LDL) cholesterol levels in all subjects before and after the start of treatment with lanthanum carbonate were 73.0±19.8 mg/dL and 72.8±22.6 mg/dL, respectively (p = 0.498). LDL cholesterol levels have observed no changes during the investigation period. This has been similar in the rosuvastatin and non-rosuvastatin groups. Serum phosphorus levels in all subjects before and after the start of lanthanum carbonate treatment were 6.6±0.9 mg/dL and 5.4±1.2 mg/dL, respectively (p＜0.01). In the rosuvastatin group, the corresponding levels were 6.2±0.8 mg/dL and 5.0±1.0 mg/dL before and after the start of treatment with lanthanum. In the non-rosuvastatin group, the corresponding levels were 6.7±0.9 mg/dL and 5.5±1.2 mg/dL before and after the start of treatment with lanthanum, with a significant reduction in the levels being observed during the investigation period (p<0.01). LDL cholesterol levels were almost unchanged in all subjects examined, and the serum phosphorus levels decreased in all subjects examined. Therefore, our results suggest that the combined use of lanthanum carbonate and rosuvastatin does not affect the clinical effect of either medication."}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"*Lanthanum(治療的利用,薬理学)","subitem_subject_scheme":"Other"},{"subitem_subject":"*LDL Cholesterol(血液)","subitem_subject_scheme":"Other"},{"subitem_subject":"Lovastatin(治療的利用,薬理学)","subitem_subject_scheme":"Other"},{"subitem_subject":"多剤併用療法","subitem_subject_scheme":"Other"},{"subitem_subject":"腹膜透析","subitem_subject_scheme":"Other"},{"subitem_subject":"薬物相互作用","subitem_subject_scheme":"Other"},{"subitem_subject":"*リン(血液)","subitem_subject_scheme":"Other"},{"subitem_subject":"*HMG-CoA Reductase Inhibitors(治療的利用,薬理学)","subitem_subject_scheme":"Other"},{"subitem_subject":"後向き研究","subitem_subject_scheme":"Other"},{"subitem_subject":"治療成績","subitem_subject_scheme":"Other"},{"subitem_subject":"Atorvastatin(治療的利用,薬理学)","subitem_subject_scheme":"Other"},{"subitem_subject":"Pitavastatin(治療的利用,薬理学)","subitem_subject_scheme":"Other"},{"subitem_subject":"高リン酸血症(病因,薬物療法)","subitem_subject_scheme":"Other"},{"subitem_subject":"慢性腎臓病(薬物療法,治療,診断)","subitem_subject_scheme":"Other"},{"subitem_subject":"*Lanthanum Carbonate(治療的利用,薬理学)","subitem_subject_scheme":"Other"},{"subitem_subject":"ヒト","subitem_subject_scheme":"Other"},{"subitem_subject":"中年(45〜64)","subitem_subject_scheme":"Other"},{"subitem_subject":"高齢者(65〜79)","subitem_subject_scheme":"Other"},{"subitem_subject":"高齢者(80〜)","subitem_subject_scheme":"Other"},{"subitem_subject":"男","subitem_subject_scheme":"Other"},{"subitem_subject":"女","subitem_subject_scheme":"Other"},{"subitem_subject":"HMG-CoA reductase inhibitor, lanthanum carbonate, drug interaction, chronic kidney disease, CKD","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"HMG-CoA還元酵素阻害薬と炭酸ランタンの併用による脂質プロファイルと血清リン値の変動に関する検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"HMG-CoA還元酵素阻害薬と炭酸ランタンの併用による脂質プロファイルと血清リン値の変動に関する検討"},{"subitem_title":"Changes in Lipid Profiles and Serum Phosphorus Levels due to combination of HMG-CoA reductase inhibitor and Lanthanum Carbonate","subitem_title_language":"en"}]},"item_type_id":"3","owner":"20","path":["312"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-06-15"},"publish_date":"2018-06-15","publish_status":"0","recid":"13246","relation_version_is_last":true,"title":["HMG-CoA還元酵素阻害薬と炭酸ランタンの併用による脂質プロファイルと血清リン値の変動に関する検討"],"weko_creator_id":"20","weko_shared_id":-1},"updated":"2023-06-19T08:57:41.468393+00:00"}